A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

NCT05938270 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Saruparib (AZD5305)
DRUG: Darolutamide
OTHER: No Treatment

Sponsor

AstraZeneca